Authors

Latest:

Dr. Adjei on Adverse Events From MEK Inhibitors

Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses eye toxicity from MEK inhibitors.

Alex E. Denes, MD

Latest:

Dr. Denes Discusses Biosimilar Pricing in Oncology

Alex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses biosimilar pricing in oncology.

Alex Herrera, MD

Latest:

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

Dr Herrera explains why N+AVD is a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma.

Alex Molasiotis, RN, PhD

Latest:

Alex Molasiotis, RN, PhD, on the Management on Breathlessness

Alex Molasiotis, RN, PhD, discusses the results of a pilot feasibility study looking at inspiratory muscle training for the management of breathlessness in patients with lung cancer.

Alexander B. Olawaiye, MD

Latest:

Dr. Olawaiye on How to Address Disparities in Cancer Care

Alexander B. Olawaiye, MD, discusses how to address disparities in cancer care.

Alexander Drilon, MD

Latest:

Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors

Dr. Alexander Drilon presents an update from the Phase 1/2 ALKOVE-1 study, investigating the efficacy and safety of NVL-655, a selective ALK inhibitor, in patients with ALK-positive solid tumors, highlighting durable responses in heavily pre-treated populations, including those with compound ALK resistance mutations and central nervous system involvement.

Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center

Latest:

Rapid Readouts: Results from two trials of TRK inhibitor, larotrectinib, in patients with TRK fusion-positive lung cancer

Alexander Drilon, MD presents data from the 2021 American Society of Clinical Oncology annual meeting from trials in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer treated with larotrectinib.

Alexander E. Drilon, MD

Latest:

Dr. Drilon on Activity of Larotrectinib in TRK Fusion-Positive NSCLC

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive non–small cell lung cancer.

Alexander E. Perl, MD

Latest:

Dr. Perl on CAR T Cells in Pediatric Leukemia

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, Perelman School of Medicine, discusses the promise of CAR T cells in the treatment of pediatric leukemia.

Alexander E. Perl, MD, MS

Latest:

Dr. Perl on Genetic Testing and Targeted Therapies in AML

Alexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.

Alexander E. Perl, MD, MS, Hospital of The University of Pennsylvania

Alexander E. Perl, MD, Perelman School of Medicine

Alexander Eggermont, MD, PhD, Institut Gustave Roussy

Alexander Guminski, MD, PhD

Latest:

Dr. Guminski on 16-Month Follow-Up With Cemiplimab in mCSCC

Alexander Guminski, MD, PhD, medical oncologist, Royal North Shore Hospital, University of Sydney, discusses the 16-month follow-up results of a phase II trial evaluating cemiplimab (Libtayo) in patients with metastatic cutaneous squamous cell carcinoma.

Alexander I. Sankin, MD

Latest:

Dr. Alexander I. Sankin on HHLA2 in Bladder Cancer

Alexander J. Stratigos, MD

Latest:

Dr. Stratigos the Rationale to Evaluate Cemiplimab in Locally Advanced BCC

Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.

Alexander Kutikov, MD

Latest:

Fox Chase Investigates Screening Methods to Avoid Unnecessary Radical Cystectomy

Currently, there is no reliable way to identify who can safely avoid radical cystectomy following MIBC treatment. For this reason, Fox Chase Cancer Center researchers are trying to find the as-yet-elusive 30% by asking 3 important questions.

Alexander Kutikov, MD, FACS

Latest:

Dr Kutikov on Therapeutic Approaches in Urothelial Cancer Requiring Cystectomy

Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.

Alexander Leandros Lazarides, MD

Latest:

Dr. Lazarides on Research Regarding Margin Assessment in Sarcoma

Alexander Leandros Lazarides, MD, discusses research regarding margin assessment in patients with sarcoma.

Alexander M. Lesokhin, MD

Latest:

Dr. Lesokhin on the Utility of Elranatamab in Relapsed/Refractory Multiple Myeloma

Alexander M. Lesokhin, MD, discusses the utility of elranatamab in the ongoing phase 2 MagnetisimMM-3 trial in relapsed/refractory multiple myeloma.